These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 6177658)

  • 1. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
    Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
    Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
    Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
    Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strain differentiation of polioviruses with monoclonal antibodies.
    Osterhaus AD; van Wezel AL; Stegmann AJ; van Asten JA; Hazendonk AG
    Dev Biol Stand; 1984; 57():135-9. PubMed ID: 6098494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and characterization of neutralizing monoclonal antibodies against poliovirus type 1, 2, and 3.
    Payment P; Trudel M; Thibodeau L; Lecomte J
    Can J Microbiol; 1989 May; 35(5):550-3. PubMed ID: 2545322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3.
    Ferguson M; Yi-hua Q; Minor PD; Magrath DI; Spitz M; Schild GC
    Lancet; 1982 Jul; 2(8290):122-4. PubMed ID: 6123838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of allogenic hybridomas for production of monoclonal antibodies against oral polio vaccine strains.
    Gupta CK; Sokhey J; Gupta RK; Singh H
    Vaccine; 1991 Nov; 9(11):853-4. PubMed ID: 1661979
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.
    Ferguson M; Magrath DI; Minor PD; Schild GC
    Bull World Health Organ; 1986; 64(2):239-46. PubMed ID: 3017595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
    Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
    J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA).
    Uhlig H; Rutter G; Dernick R
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2809-12. PubMed ID: 6198443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human-human hybridoma which produces antibodies to polioviruses.
    Chu CT; Yang SY; Yang CS
    Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):284-8. PubMed ID: 2561573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
    Ferguson M; Reed SE; Minor PD
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine.
    Horie H; Sato M; Doi Y; Hashizume S
    Vaccine; 1996 Jan; 14(1):35-41. PubMed ID: 8821647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.